Cancer Forums and News by PhD's


News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
myelodysplastic
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with MDS
By Dross at 2010-11-30 02:12
 

 In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytogenetic data of 302 patients. Patients were analyzed by karyotyping and fluorescence in situ hybridization. In 85 patients, del(5q) was only detected by karyotyping.

read more | 2 comments | 1867 reads

59-Year-Old Man with MDS
By Dross at 2009-10-23 03:36
 

Patients with MDS often ask the question "What should I do?" Here is an interesting article from the Biology of Blood and Marrow Transplantation journal that asked that very question of a number of experts.

 

read more | 1678 reads

Exjade®, a breakthrough once-daily oral iron chelator, receives first approval worldwide in the US
By Dross at 2007-10-18 02:10
 
  • Exjade offers new alternative to burdensome standard therapy in children and adults who require blood transfusions for chronic anemias
  • Approval makes iron chelation more accessible to patients suffering from diseases such as thalassemia, sickle cell and myelodysplastic syndromes

Basel, November 2, 2005 – Novartis announced today the first approval worldwide for Exjade® (deferasirox) – the first and only once-daily oral iron chelator – by the US Food and Drug Administration. Exjade has been approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.

read more | 5029 reads

Myelodysplastic Syndrome Basics I
By Dross at 2007-03-09 03:41

Myelodysplastic syndromes are a group of diseases in which the bone marrow does not make enough healthy blood cells.

 

Myelodysplastic syndromes are diseases of the blood and bone marrow. Normally, the bone marrow produces stem cells (immature cells) that develop into mature blood cells. There are 3 types of mature blood cells:

read more | 4037 reads

Myelodysplastic Syndromes
By Dross at 2007-03-08 04:01

Myelodysplastic syndromes (MDS) are a major and very personal target of this website. Because of this, I have found that I have been delaying the creation of this page as I have so much information I would like to include, all of it specific to an individual's FISH (cytogenetic, chromosomal) picture.

 

It also occurs to me that many patients that may stop by this site are missing information that could save their lives. Therefore I would like to "cut to the chase" if you will and direct you to where you should go in the meantime.

MDS is characterized by an excess of blasts in the Bone Marrow 5-20%. While you may avoid the thought of leukemiaterm when reading information on the internet, the ONLY difference between MDS and leukemia is that the term "leukemia" is only used when the number of blasts reaches 20% or more.

read more | 6 comments | 8602 reads

CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
By admin at 2006-11-18 05:26
 

BRANFORD, Conn., Nov. 16 /PRNewswire-FirstCall/ -- CuraGen Corporation (NASDAQ:CRGN)
and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of Myelodysplastic Syndromes (MDS). This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for PXD101.

read more | 2029 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 06:44 AM.